Toxicity profiling of cardiac transcription factor-targeted compounds in various cardiac and stem cell types reveals cell type-and compound-dependent toxicity

Autor: Karhu, ST, Valimaki, M, Jumppanen, M, Pohjolainen, L, Leigh, R, Foldes, G, Af Gennas, GB, Yli-Kauhaluoma, J, Ruskoaho, H, Talman, V

Publikováno v: 5th Congress of the ESC-Council-on-Basic-Cardiovascular-Science on Frontiers in Cardio Vascular Biology
S75

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1032::3e24df7e57d638bb6f668eaa12d3fddd
http://hdl.handle.net/10044/1/59087

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Expanding the Paradigm of Structure-Based Drug Design: Molecular Dynamics Simulations Support the Development of New Pyridine-Based Protein Kinase C-Targeted Agonists.

Autor: Lautala S; Drug Research Program, Division of Pharmaceutical Biosciences, University of Helsinki, P.O. Box 56 (Viikinkaari 5 E), FI-00014 Helsinki, Finland., Provenzani R; Drug Research Program, Division of Pharmaceutical Chemistry and Technology, University of Helsinki, P.O. Box 56 (Viikinkaari 5 E), FI-00014 Helsinki, Finland., Tarvainen I; Drug Research Program, Division of Pharmacology and Pharmacotherapy, University of Helsinki, P.O. Box 56 (Viikinkaari 5 E), FI-00014 Helsinki, Finland., Sirna K; Drug Research Program, Division of Pharmaceutical Chemistry and Technology, University of Helsinki, P.O. Box 56 (Viikinkaari 5 E), FI-00014 Helsinki, Finland., Karhu ST; Drug Research Program, Division of Pharmacology and Pharmacotherapy, University of Helsinki, P.O. Box 56 (Viikinkaari 5 E), FI-00014 Helsinki, Finland., Grazhdankin E; Drug Research Program, Division of Pharmaceutical Chemistry and Technology, University of Helsinki, P.O. Box 56 (Viikinkaari 5 E), FI-00014 Helsinki, Finland., Lehtinen AK; Drug Research Program, Division of Pharmaceutical Chemistry and Technology, University of Helsinki, P.O. Box 56 (Viikinkaari 5 E), FI-00014 Helsinki, Finland., Sa'd H; Drug Research Program, Division of Pharmaceutical Biosciences, University of Helsinki, P.O. Box 56 (Viikinkaari 5 E), FI-00014 Helsinki, Finland.; School of Pharmacy, The University of Jordan, Queen Rania Street, 11942 Amman, Jordan., Koivuniemi A; Drug Research Program, Division of Pharmaceutical Biosciences, University of Helsinki, P.O. Box 56 (Viikinkaari 5 E), FI-00014 Helsinki, Finland., Xhaard H; Drug Research Program, Division of Pharmaceutical Chemistry and Technology, University of Helsinki, P.O. Box 56 (Viikinkaari 5 E), FI-00014 Helsinki, Finland., Tuominen RK; Drug Research Program, Division of Pharmacology and Pharmacotherapy, University of Helsinki, P.O. Box 56 (Viikinkaari 5 E), FI-00014 Helsinki, Finland., Talman V; Drug Research Program, Division of Pharmacology and Pharmacotherapy, University of Helsinki, P.O. Box 56 (Viikinkaari 5 E), FI-00014 Helsinki, Finland., Bunker A; Drug Research Program, Division of Pharmaceutical Biosciences, University of Helsinki, P.O. Box 56 (Viikinkaari 5 E), FI-00014 Helsinki, Finland., Yli-Kauhaluoma J; Drug Research Program, Division of Pharmaceutical Chemistry and Technology, University of Helsinki, P.O. Box 56 (Viikinkaari 5 E), FI-00014 Helsinki, Finland.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2023 Apr 13; Vol. 66 (7), pp. 4588-4602. Date of Electronic Publication: 2023 Apr 03.

GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes.

Autor: Karhu ST; Drug Research Program and Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, 00014, Helsinki, Finland., Kinnunen SM; Drug Research Program and Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, 00014, Helsinki, Finland.; Department of Pharmacology and Toxicology, Institute of Biomedicine, University of Oulu, Oulu, Finland., Tölli M; Department of Pharmacology and Toxicology, Institute of Biomedicine, University of Oulu, Oulu, Finland., Välimäki MJ; Drug Research Program and Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, 00014, Helsinki, Finland.; Department of Pharmacology and Toxicology, Institute of Biomedicine, University of Oulu, Oulu, Finland., Szabó Z; Department of Pharmacology and Toxicology, Institute of Biomedicine, University of Oulu, Oulu, Finland., Talman V; Drug Research Program and Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, 00014, Helsinki, Finland.; National Heart and Lung Institute, Imperial College London, London, UK., Ruskoaho H; Drug Research Program and Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, 00014, Helsinki, Finland. heikki.ruskoaho@helsinki.fi.; Department of Pharmacology and Toxicology, Institute of Biomedicine, University of Oulu, Oulu, Finland. heikki.ruskoaho@helsinki.fi.

Publikováno v: Archives of toxicology [Arch Toxicol] 2020 Jun; Vol. 94 (6), pp. 2113-2130. Date of Electronic Publication: 2020 Mar 17.

Stem cells are the most sensitive screening tool to identify toxicity of GATA4-targeted novel small-molecule compounds.

Autor: Karhu ST; Drug Research Program and Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, 00014, Helsinki, Finland., Välimäki MJ; Drug Research Program and Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, 00014, Helsinki, Finland.; Department of Pharmacology and Toxicology, Institute of Biomedicine, University of Oulu, Oulu, Finland., Jumppanen M; Drug Research Program and Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, 00014, Helsinki, Finland., Kinnunen SM; Drug Research Program and Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, 00014, Helsinki, Finland.; Department of Pharmacology and Toxicology, Institute of Biomedicine, University of Oulu, Oulu, Finland., Pohjolainen L; Drug Research Program and Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, 00014, Helsinki, Finland., Leigh RS; Drug Research Program and Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, 00014, Helsinki, Finland., Auno S; Drug Research Program and Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, 00014, Helsinki, Finland., Földes G; National Heart and Lung Institute, Imperial College London, London, UK.; Heart and Vascular Center, Semmelweis University, Budapest, Hungary., Boije Af Gennäs G; Drug Research Program and Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, 00014, Helsinki, Finland., Yli-Kauhaluoma J; Drug Research Program and Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, 00014, Helsinki, Finland., Ruskoaho H; Drug Research Program and Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, 00014, Helsinki, Finland., Talman V; Drug Research Program and Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, 00014, Helsinki, Finland. virpi.talman@helsinki.fi.

Publikováno v: Archives of toxicology [Arch Toxicol] 2018 Sep; Vol. 92 (9), pp. 2897-2911. Date of Electronic Publication: 2018 Jul 09.